KRAS and alkaline phosphatase measurement: Our data and others show that caerulein-induced AP acts as cancer promoter in PDAC mouse models [14], [15], [16], suggesting that AP, when occurring in an individual whose pancreas harbors a Kras mutation, could potentially increase PDAC risk.